Skip to main content
. 2019 Dec 5;4(23):e131886. doi: 10.1172/jci.insight.131886

Figure 5. C4BP-IgM promotes complement-mediated killing of N. gonorrhoeae.

Figure 5

(A–D) Complement-dependent bactericidal activity of C4BP-IgM on 4 laboratory strains of N. gonorrhoeae. Strains MS11 (A) and 1291 (B) were incubated with 5% NHS, while strains 15253 (C) and FA1090 (D) were tested with 20% NHS. Heat-inactivated NHS (HI NHS) was used as a negative control. One-way ANOVA with Dunnett’s multiple-comparisons test was performed considering NHS as reference. (E–G) Complement-mediated bactericidal activity of 20 μg/mL C4BP-IgM in 10% NHS on FA1090, MS11 and F62 in the presence (w SA) or in the absence (w/o SA) of LOS. P values were calculated by 2-way ANOVA with Tukey’s multiple comparison of log10 (CFU/mL). (H) Complement-mediated bactericidal activity of 20 μg/mL C4BP-IgM on 26 clinical isolates of N. gonorrhoeae in the presence of 10% NHS. P values were performed by 2-way ANOVA with Sidak’s multiple-comparisons test. In all graphs horizontal dotted line refers to the starting amount of bacteria used in the assay, and each bar represents the mean ± SD of at least 3 independently performed experiments. *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.0001 as indicated, or compared with NHS.